ABO exam phase-in application ends April 30

Article

Interested in becoming ABO certified? Qualifications will change at the end of the month.

The American Board of Optometry (ABO) reminds optometrists that as of April 30, qualifying for the ABO exam under the rules of the 3-year phase-in period expires.

ODs can still become board certified after the phase-in period ends. However, effective May 1, Experience in Active Clinical Practice and Fellowship in the College of Optometrists in Vision Development will no longer be accepted as part of the qualification. Requirements for Category 1 and 2 Education will remain unchanged.

To qualify under the rules of the phase-in period, candidates must complete the following:

•    Apply to become an active candidate no later than April 30.

•    Submit their post-graduate requirements for verification by the ABO no later than June 30.

•    Take the ABO Board Certification Examination no later than January 2014, date of the last exam using phase-in rules.

For more information, visit the ABO Web site at www.americanboardofoptometry.org or e-mail info@abopt.org.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.